Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Why Intra-Cellular Therapies Stock Rose 21.4% This Week

TheMotleyFool

0 0

Why Intra-Cellular Therapies Stock Rose 21.4% This WeekPhoto, wide shot, wide-angle lens, Pharmaceutical company, Midday, harsh overhead sunlight, directional sunlightt, photo by Art Wolfe: https://img.midjourneyapi.xyz/temp/7ae4a134-dd01-4c80-a621-18399f5a2541.png

Intra-Cellular Therapies (NASDAQ: ITCI), a biotech that specializes in therapies to treat complex psychiatric and neurologic diseases, saw its shares rise 21.4% this week through today's close, according to data from S&P Global Market Intelligence. The stock is up more than 3% so far this year.

Image source: Getty Images.

The company released its first-quarter report on Tuesday. Revenue was $35 million, up 120% year over year. The big driver was the company's once-daily antipsychotic pill Caplyta (lumateperone).

Source Fool.com

Like: 0

ITCI

Share